I haven’t been too happy with my blood work with CLL, but I try to enjoy what I can — including apples during fall.

Among patients with ER-positive/HER2-negative advanced breast cancer, treatment with camizestrant in combination with Kisqali ...

Adjuvant Lynparza remains beneficial for patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, study results have shown.

Jaypirca showed superior progression-free survival and lower discontinuation rates versus standard treatments in patients ...

Autologous stem cell transplant plus Rituxan did not improve survival outcomes in certain patients with mantle cell lymphoma ...

Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant ...

A Phase 3 trial of uproleselan failed to improve overall survival in relapsed/refractory AML, though it may benefit primary ...

Gratitude is actively practiced, even amidst personal losses and living with metastatic cancer, highlighting its importance ...

In an interview with CURE ®, Maggie Bushway reflected on rediscovering her childhood writings and her father's blog posts ...

Patients with newly diagnosed multiple myeloma experienced robust clinical activity when treated with Tecvayli (teclistamab) ...

Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care ...

Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in ...